PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression

Cell Reports

Volumn 21, Issue 12, 2017, Pages 3498-3513

  Chiang, Kelly ^a   Zielinska, Agnieszka E ^a   Shaaban, Abeer M ^a   Sanchez Bailon, Maria Pilar ^a   Jarrold, James ^a   Clarke, Thomas L ^a   Zhang, Jingxian ^e   Francis, Adele ^a   Jones, Louise J ^c   Smith, Sally ^c   Barbash, Olena ^d   Guccione, Ernesto ^e,f   Farnie, Gillian ^b   Smalley, Matthew J ^g   Davies, Clare C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

arginine methylation; breast cancer; breast cancer stem cell; drug resistance; epigenetics; FOXP1; H3R2me2s; histone methylation; PRMT5; self renewal

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; PROTEIN ARGININE METHYLTRANSFERASE 5; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; ENZYME INHIBITOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; PRMT5 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CELL COUNT; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; HISTONE METHYLATION; IN VITRO STUDY; IN VIVO STUDY; MCF-7 CELL LINE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA SEQUENCE; SURVIVAL RATE; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECT; FEMALE; GENETIC EPIGENESIS; GENETICS; HISTONE CODE; HUMAN; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; SCID MOUSE;

ANIMALS; BREAST NEOPLASMS; CELL PROLIFERATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HISTONE CODE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PROTEIN-ARGININE N-METHYLTRANSFERASES; REPRESSOR PROTEINS;

EID: 85039971841     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.11.096     Document Type: Article

References (47)

1. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U S A 100 (2003), 3983–3988.
2. Baldwin, R.M., Morettin, A., Paris, G., Goulet, I., Côté J., Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. Cell Cycle 11 (2012), 4597–4612.
3. Banasavadi-Siddegowda, Y.K., Russell, L., Frair, E., Karkhanis, V.A., Relation, T., Yoo, J.Y., Zhang, J., Sif, S., Imitola, J., Baiocchi, R., Kaur, B., PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells. Oncogene 36 (2017), 263–274.
4. Bezzi, M., Teo, S.X., Muller, J., Mok, W.C., Sahu, S.K., Vardy, L.A., Bonday, Z.Q., Guccione, E., Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev. 27 (2013), 1903–1916.
5. Blanc, R.S., Vogel, G., Li, X., Yu, Z., Li, S., Richard, S., Arginine methylation by PRMT1 regulates muscle stem cell fate. Mol. Cell. Biol., 37, 2017 e00457-16.
6. Brown, P.J., Ashe, S.L., Leich, E., Burek, C., Barrans, S., Fenton, J.A., Jack, A.S., Pulford, K., Rosenwald, A., Banham, A.H., Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 111 (2008), 2816–2824.
7. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
8. Chan-Penebre, E., Kuplast, K.G., Majer, C.R., Boriack-Sjodin, P.A., Wigle, T.J., Johnston, L.D., Rioux, N., Munchhof, M.J., Jin, L., Jacques, S.L., et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat. Chem. Biol. 11 (2015), 432–437.
9. Chang, C.-J., Yang, J.-Y., Xia, W., Chen, C.-T., Xie, X., Chao, C.-H., Woodward, W.A., Hsu, J.-M., Hortobagyi, G.N., Hung, M.-C., EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 19 (2011), 86–100.
10. Chen, H., Lorton, B., Gupta, V., Shechter, D., A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene 36 (2017), 373–386.
11. Chittka, A., Nitarska, J., Grazini, U., Richardson, W.D., Transcription factor positive regulatory domain 4 (PRDM4) recruits protein arginine methyltransferase 5 (PRMT5) to mediate histone arginine methylation and control neural stem cell proliferation and differentiation. J. Biol. Chem. 287 (2012), 42995–43006.
12. Choi, E.J., Seo, E.J., Kim, D.K., Lee, S.-I., Kwon, Y.W., Jang, I.H., Kim, K.-H., Suh, D.-S., Kim, J.H., FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget 7 (2016), 3506–3519.
13. Clarke, T.L., Sanchez-Bailon, M.P., Chiang, K., Reynolds, J.J., Herrero-Ruiz, J., Bandeiras, T.M., Matias, P.M., Maslen, S.L., Skehel, J.M., Stewart, G.S., Davies, C.C., PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination. Mol. Cell 65 (2017), 900–916.e7.
14. Dacwag, C.S., Ohkawa, Y., Pal, S., Sif, S., Imbalzano, A.N., The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling. Mol. Cell. Biol. 27 (2007), 384–394.
15. Di Lorenzo, A., Bedford, M.T., Histone arginine methylation. FEBS Lett. 585 (2011), 2024–2031.
16. Duncan, K.W., Rioux, N., Boriack-Sjodin, P.A., Munchhof, M.J., Reiter, L.A., Majer, C.R., Jin, L., Johnston, L.D., Chan-Penebre, E., Kuplast, K.G., et al. Structure and property guided design in the identification of PRMT5 tool compound EPZ015666. ACS Med. Chem. Lett. 7 (2015), 162–166.
17. Feinberg, A.P., Koldobskiy, M.A., Göndör, A., Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17 (2016), 284–299.
18. Fillmore, C.M., Kuperwasser, C., Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 10, 2008, R25.
19. Gabut, M., Samavarchi-Tehrani, P., Wang, X., Slobodeniuc, V., O'Hanlon, D., Sung, H.-K., Alvarez, M., Talukder, S., Pan, Q., Mazzoni, E.O., et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 147 (2011), 132–146.
20. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6, 2013, pl1.
21. Ginestier, C., Hur, M.-H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007), 555–567.
22. Goulet, I., Gauvin, G., Boisvenue, S., Côté J., Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J. Biol. Chem. 282 (2007), 33009–33021.
23. Goyal, A., Chavez, S.L., Reijo Pera, R.A., Generation of human induced pluripotent stem cells using epigenetic regulators reveals a germ cell-like identity in partially reprogrammed colonies. PLoS ONE, 8, 2013, e82838.
24. Grebien, F., Vedadi, M., Getlik, M., Giambruno, R., Grover, A., Avellino, R., Skucha, A., Vittori, S., Kuznetsova, E., Smil, D., et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat. Chem. Biol. 11 (2015), 571–578.
25. Györffy, B., Lánczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., Szállási, Z., An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123 (2010), 725–731.
26. Harrison, H., Farnie, G., Howell, S.J., Rock, R.E., Stylianou, S., Brennan, K.R., Bundred, N.J., Clarke, R.B., Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70 (2010), 709–718.
27. Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013), 714–726.
28. Huang, D.W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 4 (2009), 44–57.
29. Jin, Y., Zhou, J., Xu, F., Jin, B., Cui, L., Wang, Y., Du, X., Li, J., Li, P., Ren, R., Pan, J., Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J. Clin. Invest. 126 (2016), 3961–3980.
30. Liu, F., Cheng, G., Hamard, P.-J., Greenblatt, S., Wang, L., Man, N., Perna, F., Xu, H., Tadi, M., Luciani, L., Nimer, S.D., Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. J. Clin. Invest. 125 (2015), 3532–3544.
31. Migliori, V., Müller, J., Phalke, S., Low, D., Bezzi, M., Mok, W.C., Sahu, S.K., Gunaratne, J., Capasso, P., Bassi, C., et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat. Struct. Mol. Biol. 19 (2012), 136–144.
32. Muñoz, P., Iliou, M.S., Esteller, M., Epigenetic alterations involved in cancer stem cell reprogramming. Mol. Oncol. 6 (2012), 620–636.
33. Nagamatsu, G., Kosaka, T., Kawasumi, M., Kinoshita, T., Takubo, K., Akiyama, H., Sudo, T., Kobayashi, T., Oya, M., Suda, T., A germ cell-specific gene, Prmt5, works in somatic cell reprogramming. J. Biol. Chem. 286 (2011), 10641–10648.
34. Naudin, C., Hattabi, A., Michelet, F., Miri-Nezhad, A., Benyoucef, A., Pflumio, F., Guillonneau, F., Fichelson, S., Vigon, I., Dusanter-Fourt, I., Lauret, E., PUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells. Blood 129 (2017), 2493–2506.
35. Oskay Halacli, S., FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells. Cell Biol. Int. 41 (2017), 102–110.
36. Pal, S., Vishwanath, S.N., Erdjument-Bromage, H., Tempst, P., Sif, S., Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 24 (2004), 9630–9645.
37. Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., Pilotti, S., Pierotti, M.A., Daidone, M.G., Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65 (2005), 5506–5511.
38. Powers, M.A., Fay, M.M., Factor, R.E., Welm, A.L., Ullman, K.S., Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 71 (2011), 5579–5587.
39. Scoumanne, A., Zhang, J., Chen, X., PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res. 37 (2009), 4965–4976.
40. Shigekawa, T., Ijichi, N., Ikeda, K., Horie-Inoue, K., Shimizu, C., Saji, S., Aogi, K., Tsuda, H., Osaki, A., Saeki, T., Inoue, S., FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm. Cancer 2 (2011), 286–297.
41. Tam, W.L., Weinberg, R.A., The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19 (2013), 1438–1449.
42. Tee, W.-W., Pardo, M., Theunissen, T.W., Yu, L., Choudhary, J.S., Hajkova, P., Surani, M.A., Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev. 24 (2010), 2772–2777.
43. Wu, Y., Wang, Y., Yang, X.H., Kang, T., Zhao, Y., Wang, C., Evers, B.M., Zhou, B.P., The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 5 (2013), 224–236.
44. Xiao, J., He, B., Zou, Y., Chen, X., Lu, X., Xie, M., Li, W., He, S., You, S., Chen, Q., Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis. Sci. Rep., 6, 2016, 30437.
45. Yang, F., Wang, J., Ren, H.-Y., Jin, J., Wang, A.-L., Sun, L.-L., Diao, K.-X., Wang, E.-H., Mi, X.-Y., Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression. Tumour Biol. 36 (2015), 5901–5911.
46. Zhang, T., Günther, S., Looso, M., Künne, C., Krüger, M., Kim, J., Zhou, Y., Braun, T., Prmt5 is a regulator of muscle stem cell expansion in adult mice. Nat. Commun., 6, 2015, 7140.
47. Zhao, Q., Rank, G., Tan, Y.T., Li, H., Moritz, R.L., Simpson, R.J., Cerruti, L., Curtis, D.J., Patel, D.J., Allis, C.D., et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 16 (2009), 304–311.